Ran Fisher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ran Fisher has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Michal Kaufmann Yehezkely
Faculty of Medicine, Hebrew University, Jerusalem, Israel
2 shared publications - Nir Hirshoren
Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem. Israel
2 shared publications - Sagit Stern Shavit
Department of Otolaryngology–Head & Neck Surgery, Hadassah Medical Center and the Faculty of Medicine Hebrew University Jerusalem Israel
2 shared publications - Yehuda Tarnovsky
Faculty of Medicine Hebrew University of Jerusalem Jerusalem Israel
2 shared publications - Gaelle Vofo
Department of Otolaryngology-Head & Neck Surgery, Hadassah-Hebrew University Medical Centre, Jerusalem 91120, Israel
1 shared publication Haggi Mazeh
Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem. Israel
1 shared publication
Latest Publications
- Open Access
- 29 September 2026
- Published by Elsevier in Surgery in Practice and Science
- Vol. 27, 100364
Cautious clinical interpretation of preoperative Tc-99m-Sestamibi localization scan among chronic kidney disease and transplanted patients
- 29 September 2026
- Published by Elsevier in Surgery in Practice and Science
- Vol. 27, 100364
Open AccessCautious clinical interpretation of preoperative Tc-99m-Sestamibi localization scan among chronic kidney disease and transplanted patients
- Open Access
- 13 October 2024
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 172 (2) , 509-516
Prognostic Significance of Early Posttreatment Audiometry in Idiopathic Sudden Sensorineural Hearing Loss
Objective: This study aimed to assess the prognostic value of early posttreatment initiation audiometry findings in patients with idiopathic sudden sensorineural hearing loss (ISSHL).Study Design: A retrospective cohort study.Setting: The study was conducted at a single tertiary medical center.Methods: A review was conducted on 299 ISSHL patients treated between 2007 and 2023. Patients underwent audiometry on Days 2 to 3 and 5 to 7 posttreatment initiation. Data on demographics, medical history, audiometry results, and prognosis were collected. Prognosis was categorized based on hearing recovery at 1 year postdiagnosis.Results: Older age, worse initial speech reception threshold (SRT), ischemic heart disease, cerebrovascular accidents/transient ischemic attacks, hypertension, and diabetes were associated with a poorer prognosis. Posttreatment initiation audiometry findings on Days 2 to 3 and 5 to 7 significantly correlated with prognosis. Patients with a ≥30% improvement had substantial or complete recovery in over 80% of cases, while those with P = .0002).Conclusion: Posttreatment initiation audiometry findings, particularly on Days 5 to 7, hold significant prognostic value in ISSHL patients. A substantial improvement during this timeframe is strongly associated with favorable outcomes. These findings emphasize the potential of posttreatment initiation audiometry as a valuable tool for clinicians in counseling patients with ISSHL.
- 13 October 2024
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 172 (2) , 509-516
Open AccessPrognostic Significance of Early Posttreatment Audiometry in Idiopathic Sudden Sensorineural Hearing Loss
Objective: This study aimed to assess the prognostic value of early posttreatment initiation audiometry findings in patients with idiopathic sudden sensorineural hearing loss (ISSHL).Study Design: A retrospective cohort study.Setting: The study was conducted at a single tertiary medical center.Methods: A review was conducted on 299 ISSHL patients treated between 2007 and 2023. Patients underwent audiometry on Days 2 to 3 and 5 to 7 posttreatment initiation. Data on demographics, medical history, audiometry results, and prognosis were collected. Prognosis was categorized based on hearing recovery at 1 year postdiagnosis.Results: Older age, worse initial speech reception threshold (SRT), ischemic heart disease, cerebrovascular accidents/transient ischemic attacks, hypertension, and diabetes were associated with a poorer prognosis. Posttreatment initiation audiometry findings on Days 2 to 3 and 5 to 7 significantly correlated with prognosis. Patients with a ≥30% improvement had substantial or complete recovery in over 80% of cases, while those with P = .0002).Conclusion: Posttreatment initiation audiometry findings, particularly on Days 5 to 7, hold significant prognostic value in ISSHL patients. A substantial improvement during this timeframe is strongly associated with favorable outcomes. These findings emphasize the potential of posttreatment initiation audiometry as a valuable tool for clinicians in counseling patients with ISSHL.
- Open Access
- 17 February 2023
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 280 (8) , 3609-3613
The association between COVID-19 vaccination and idiopathic sudden sensorineural hearing loss, clinical manifestation and outcomes
Purpose Previous data demonstrated an increased incidence of Idiopathic Sensorineural Hearing Loss (ISSNHL) in 2021 compared to 2019–2020, suggesting an association with the anti-COVID-19 vaccine. We aimed to assess our center’s incidence and compare the clinical manifestations and outcomes of vaccinated vs. unvaccinated patients. Methods A retrospective chart review of all patients diagnosed with ISSNHL during 2021 was conducted and compared to patients who presented in 2018–2020. Patient demographics, audiometry features, vaccination status, and prognosis were evaluated. Results Throughout 2021, 51 patients were diagnosed with ISSNHL, compared with 31 during 2020, 38 in 2019, and 41 in 2018, demonstrating a 64%, 34%, and 24% increase, respectively. Among patients who presented in 2021, 13 (25.4%) received the anti-COVID-19 vaccine within 30 days before their presentation, and 4 received it within 96 h. Most presented after receiving the second or third dose. Patient characteristics, audiometry features, and prognosis did not significantly differ between vaccinated and unvaccinated patients. Conclusions A marked incline was seen in the 2021 ISSNHL incidence at our medical center, of which 25% of cases were within a month post-anti-COVID-19 vaccination. No significant difference was found in clinical manifestations and outcomes between vaccinated and nonvaccinated patients. While other justifications could be sought, an association cannot be ruled out, and further research is needed.
- 17 February 2023
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 280 (8) , 3609-3613
Open AccessThe association between COVID-19 vaccination and idiopathic sudden sensorineural hearing loss, clinical manifestation and outcomes
Purpose Previous data demonstrated an increased incidence of Idiopathic Sensorineural Hearing Loss (ISSNHL) in 2021 compared to 2019–2020, suggesting an association with the anti-COVID-19 vaccine. We aimed to assess our center’s incidence and compare the clinical manifestations and outcomes of vaccinated vs. unvaccinated patients. Methods A retrospective chart review of all patients diagnosed with ISSNHL during 2021 was conducted and compared to patients who presented in 2018–2020. Patient demographics, audiometry features, vaccination status, and prognosis were evaluated. Results Throughout 2021, 51 patients were diagnosed with ISSNHL, compared with 31 during 2020, 38 in 2019, and 41 in 2018, demonstrating a 64%, 34%, and 24% increase, respectively. Among patients who presented in 2021, 13 (25.4%) received the anti-COVID-19 vaccine within 30 days before their presentation, and 4 received it within 96 h. Most presented after receiving the second or third dose. Patient characteristics, audiometry features, and prognosis did not significantly differ between vaccinated and unvaccinated patients. Conclusions A marked incline was seen in the 2021 ISSNHL incidence at our medical center, of which 25% of cases were within a month post-anti-COVID-19 vaccination. No significant difference was found in clinical manifestations and outcomes between vaccinated and nonvaccinated patients. While other justifications could be sought, an association cannot be ruled out, and further research is needed.